Study provides new update on global cancer burden

Bottom Line: Population aging and growth largely fueled an increase in cancer cases between 2006 and 2016, and large disparities continue to exist between countries in cancer incidence, deaths and the disease's associated disability.

Why The Research Is Interesting: An assessment of the impact of cancer over time can help to frame policy discussions, resource allocation and research focus.

What and When: Cancer incidence, mortality and related disability evaluated for 195 countries and territories with a focus on changes in the last decade (2006-2016).

Study Design: This was a systematic analysis.

Authors: Christina Fitzmaurice, M.D., M.P.H., at the Institute for Health Metrics and Evaluation at the University of Washington, Seattle, and coauthors in the Global Burden of Disease Cancer Collaboration

Results:

  • 17.2 million cancer cases worldwide and 8.9 million deaths in 2016
  • Cancer cases up 28% in 2006-2016; population aging, growth were drivers
  • Prostate cancer most common cancer for men
  • Breast cancer most common cancer for women

Limitations: Estimations can vary widely; data collection would be improved through the expansion and creation of vital registration systems, cancer registries, health surveys and other data systems

Study Conclusions: Cancer control planning and implementation, along with strategic investments, are needed to fulfill global commitments for the control of cancer and noncommunicable diseases.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Scientists map cancer mutations in EGFR gene, revealing drug resistance paths